Results 81 to 90 of about 19,315 (197)

Ticagrelor in Preventing Recurrent Stroke

, 2022
The purpose of this article is to review the effectiveness and safety of ticagrelor in the prevention of recurrent stroke in patients who are diagnosed with ischemic stroke and/or transient ischemic attack (TIA). Ticagrelor is an antiplatelet therapy. It
Ohi, Humaira
core  

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1787-1808, June 2026.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Ticagrelor for Neuroendovascular Procedures: A Case Series

, 2017
Background: The development of thromboembolism is one of the most common complications of neuroendovascular procedures. Although several small studies have deemed clopidogrel safe and effective in the prevention of intracranial stent thrombosis ...
Kyle Davis, Christopher Morrison
core   +1 more source

Ticagrelor alters the membrane of Staphylococcus aureus and enhances the activity of vancomycin and daptomycin without eliciting cross-resistance

mBio
Infections with multidrug-resistant bacteria pose a major healthcare problem which urges the need for novel treatment options. Besides its potent antiplatelet properties, ticagrelor has antibacterial activity against Gram-positive bacteria, including ...
Kirsten Leeten, Nicolas Jacques, Lidia Alejo Esquembre, Dana C. Schneider, Jan Straetener, Camilla Henriksen, Lucia Musumeci, Florence Putters, Sofia Melo, Elena Sánchez-López, Martin Giera, Noémie Penoy, Géraldine Piel, Olivier Verlaine, Ana Amoroso, Bernard Joris, Christoph J. Slavetinsky, Eric Goffin, Bernard Pirotte, Dorte Frees, Heike Brötz-Oesterhelt, Patrizio Lancellotti, Cécile Oury   +22 more
doaj   +1 more source

Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial

Cardiovascular Diabetology, 2019
Background Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE).
Robert S. Rosenson, Qinzhong Chen, Sherwin D. Najera, Prakash Krishnan, Martin L. Lee, Daniel J. Cho   +5 more
doaj   +1 more source

Variability in ACT Response to Standard UFH Bolus During PCI: A Prospective Study on Determinants of Subtherapeutic Anticoagulation

Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2293-2303, June 1, 2026.
ABSTRACT Background Unfractionated heparin (UFH) remains the standard anticoagulant during percutaneous coronary intervention (PCI), with guidelines recommending a target activated clotting time (ACT) of ≥250 s. However, despite receiving a standardized bolus dose, many patients fail to achieve this target.
Manh Cuong Vu, Antonin Trimaille, Amandine Granier, Adrien Carmona, Anis Elidrissi, Marion Kibler, Laurence Jesel, Patrick Ohlmann, Laurent Sattler, Olivier Morel   +9 more
wiley   +1 more source

Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies

Indian Heart Journal, 2019
Objective: We aimed to assess the efficacy and safety of ticagrelor compared to clopidogrel in Asian patients with acute coronary syndrome (ACS) in real-world practice.
Akhmetzhan Maratovich Galimzhanov, Baurzhan Slymovich Azizov   +1 more
doaj   +1 more source

Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 6, June 2026.
ABSTRACT Background High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its ...
Emad Uddin Sajid, Muhammad Hasnain Azeem, Alishba Fatima, Syeda Masooma Jafri, Danish Hassan, Taha Ibrahim, Kashish Zehra Manjee, Syed Rayyan Ahmed, Tooba Ali, Rida Shakeel, Muhammad Usman, Raghabendra Kumar Mahato, Danish Bawa   +12 more
wiley   +1 more source

Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin

, 2017
Background: Ticagrelor, a P2Y12 antagonist, is approved for the prevention of thromboembolic events. However, antiplatelet therapies carry a risk of bleeding. Objective: To explore the hemostatic effects of MEDI2452, an antidote for ticagrelor.
Gennemark, Peter, Sandinge, A. S., A.‐S. Sandinge, Johansson, K. J.,, Almqvist, Joachim E,, J. Sanchez, Almqvist, Joachim E, Sandinge, A. S.,, Sanchez, J., Johansson, K. J., Nylander, S.,, Janefeldt, A., Goodman, J.,, J. Goodman, Gennemark, P., K. J Johansson, Maqbool, S., Pehrsson, S., S. Nylander, Goodman, J., Gennemark, Peter,, Maqbool, S.,, Almquist, Joachim, S. Pehrsson, S. Maqbool, Pehrsson, S.,, P. Gennemark, A. Janefeldt, Janefeldt, A.,, Nylander, S., J. Almquist, Sanchez, J.,   +31 more
core   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1547-1554, June 2026.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon, Chen Gurevitz, Tzippy Shochat, Shiri Kushnir, Guy Witberg, Amos Levi, Dan Gilon, Ran Kornowski, Paaladinesh Thavendiranathan, Husam Abdel Qadir, Zaza Iakobishvili   +10 more
wiley   +1 more source